Sandra Schuldheisz, MD
Pulmonary Disease · Somerset, KYNPI 1194798934
Payments from drug & device makers
Across 795 payments — averaging $282.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$87K
- Sunovion Pharmaceuticals Inc.$45K
- Boehringer Ingelheim$34K
- Mylan Specialty L.p.$34K
- Intuitive Surgical$10K
- Viatris Specialty LLC$10K
- plus $4K from 21 others
What the payments were for
- Consulting fees$8500%
- Speaking & faculty fees$191,72285%
- Travel & lodging$11,5955%
- Food & beverage$11,0815%
- Education$9,3334%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 181 | $86,603 |
| Sunovion Pharmaceuticals Inc. | 175 | $45,414 |
| Boehringer Ingelheim | 90 | $34,323 |
| Mylan Specialty L.p. | 61 | $34,241 |
| Intuitive Surgical | 18 | $10,378 |
| Viatris Specialty LLC | 32 | $9,756 |
| Grifols USA, LLC | 128 | $1,246 |
| AstraZeneca | 19 | $555 |
| Jazz Pharmaceuticals Inc. | 17 | $518 |
| Harmony Biosciences LLC | 15 | $304 |
| Amgen | 17 | $304 |
| UCB, Inc. | 12 | $197 |
| Inspire Medical Systems, Inc. | 4 | $188 |
| Verona Pharma, Inc. | 6 | $133 |
| ERBE USA Inc | 1 | $100 |
| Merck | 5 | $71 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| Circassia Inc. | 2 | $34 |
| Mallinckrodt Enterprises LLC | 1 | $25 |
| United Therapeutics Corporation | 1 | $23 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $20 |
| Optinose US, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Covis Pharma GmbH | 1 | $15 |
| Baxter Healthcare | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$52,452
- Yupelri$42,785
- LONHALA MAGNAIR$42,311
- Da Vinci Surgical System$10,223
- STIOLTO RESPIMAT$850
- LATUDA$760
- XYWAV$100
- ErbeCryo2$100
- Inspire$100
How this compares
$224,581 in reported general payments places this provider in the 95th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 603 | $493,426 |
| XyremSodium Oxybate | 12 | $250,990 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 293 | $249,629 |
| WakixPitolisant Hcl | 12 | $195,524 |
| Breo ElliptaFluticasone/Vilanterol | 192 | $91,881 |
| Spiriva RespimatTiotropium Bromide | 131 | $77,479 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 129 | $69,422 |
| Spiriva HandihalerTiotropium Bromide | 105 | $61,387 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 98 | $56,090 |
| ProvigilModafinil | 13 | $48,426 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 67 | $41,923 |
| Incruse ElliptaUmeclidinium Bromide | 86 | $41,245 |
| BelsomraSuvorexant | 69 | $31,092 |
| Advair HfaFluticasone Propion/Salmeterol | 73 | $26,204 |
| YupelriRevefenacin | 14 | $19,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $86,603 | $707,8991,053 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $555 | $262,931334 claims |
| Harmony Biosciences LLCWakix | $304 | $195,52412 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $34,323 | $175,492296 claims |
| MerckBelsomra, Dulera | $71 | $42,11592 claims |
| Mylan Specialty L.p.Yupelri | $34,241 | $19,71914 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $45 | $9,48121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Somerset
- Mateen AhmedSomerset$15K
- John McConnellLouisville$3.5M
- Girish NairLexington$852K
- Sally SulimanLouisville$472K
- Mohamed SaadLouisville$440K
- David WinslowLouisville$431K
- Firas KouraGeorgetown$423K
- Erica GregonisRichmond$390K
- Karim El-KershLouisville$379K
- Harold HallerLouisville$369K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.